Nepal

in page functions
[French]
Nepal
Total population (2016) 28,850,639
Birth cohort (2016) 577,535
Surviving Infants (surviving to 1 year per year, 2016) 561,632
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 29/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 36/1000
World Bank Index, IDA (2012) 3.29
Co-financing status (2016) Initial self-financing
No. of districts/territories (2015) 75

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Nepal

Type of support

Approvals

2001-2021 (US$)
(20 Dec 2016)

Commitments

2001-2021 (US$)
(20 Dec 2016)

Disbursements

2000-2016 (US$)
(20 Dec 2016)

% Disbursed

(20 Dec 2016)
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Total $130,474,147 $151,379,147 $110,982,710
Cash Support (CASHSUPP) $199,000 $224,000 $199,000 100%
Health system strengthening (HSS 1) $8,667,000 $8,667,000 $8,667,000 100%
Health system strengthening (HSS 2) $14,483,745 $14,483,745 $14,483,745 100%
Health system strengthening (HSS 3) $15,660,000 $36,540,000
HepB mono (NVS) $1,870,980 $1,870,980 $1,870,980 100%
HPV Demo (NVS) $303,500 $303,500 $317,257 105%
Immunisation services support (ISS) $3,312,520 $3,312,520 $3,312,520 100%
Injection Safety Devices (NVS) $162,000 $162,000
Injection safety support (INS) $1,151,893 $1,151,893 $1,151,893 100%
IPV (NVS) $3,494,418 $3,494,418 $2,731,976 78%
JEV (NVS) $1,921,000 $1,921,000 $2,149,466 112%
JEV - Operational costs (OPC) $2,374,000 $2,374,000 $2,374,000 100%
Measles (NVS) $865,000 $865,000 $368,784 43%
Penta (NVS) $38,219,206 $38,219,206 $35,413,185 93%
Pneumo (NVS) $26,461,500 $26,461,500 $26,614,519 101%
Tetra DTP-HepB (NVS) $8,690,385 $8,690,385 $8,690,385 100%
Vaccine Introduction Grant (VIG) $2,638,000 $2,638,000 $2,638,000 100%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Nepal DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2015)

Grade of confidence


N/A
DTP3 - Official country estimates (2015) 91%
M:F sex ratio at birth (2016) 1.07
Household survey: DTP3 coverage for male (2010) 92.10%
Household survey: DTP3 coverage for female (2010) 91.30%
Household survey: Last DTP3 survey (2010) 92%
% districts achieving > 80% DTP3 coverage (2015) 87%
% districts achieving < 50% DTP3 coverage (2015) 0%
MCV WHO/UNICEF estimates (2015) 85%

Breakdown of support

Non-vaccine support Vaccine support
30% 70%
$32,826,158 $78,156,548

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Nepal

11 November 2016

Feature 2 Nepal BG

Fighting pneumonia in Nepal: making numbers count

At Kathmandu’s Patan hospital, Gavi is funding impact studies on two vaccines that protect children against the main causes of deadly pneumonia: Haemophilus influenzae type b (Hib) and pneumococcal disease. Three doctors who are leading these studies identify four ways in which Patan’s pioneering research is shaping Nepal’s immunisation policy.

30 June 2016

Gavi default item

Gavi Board reappoints WHO's Flavia Bustreo as vice-chair

Board also confirms appointment of four new members and two alternates.

29 June 2016

Making numbers count: fighting pneumonia in Nepal

Clinical research funded by Gavi partners at Patan Hospital in Kathmandu is helping shape Nepal’s immunisation policy against its biggest child killer: pneumonia. This video shows how disease burden and impact studies at Patan have guided the national introduction of Haemophilus influenzae type b and pneumococcal vaccines, which protect children against the two main causes of pneumonia.

close icon

modal window here